ORIC Pharmaceuticals (ORIC) Competitors $5.71 +0.05 (+0.88%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORIC vs. VERA, TVTX, GPCR, MESO, EVO, INDV, OCUL, CALT, AMPH, and ARDXShould you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Vera Therapeutics (VERA), Travere Therapeutics (TVTX), Structure Therapeutics (GPCR), Mesoblast (MESO), Evotec (EVO), Indivior (INDV), Ocular Therapeutix (OCUL), Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. ORIC Pharmaceuticals vs. Vera Therapeutics Travere Therapeutics Structure Therapeutics Mesoblast Evotec Indivior Ocular Therapeutix Calliditas Therapeutics AB (publ) Amphastar Pharmaceuticals Ardelyx Vera Therapeutics (NASDAQ:VERA) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk. Does the MarketBeat Community believe in VERA or ORIC? ORIC Pharmaceuticals received 31 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 75.00% of users gave ORIC Pharmaceuticals an outperform vote while only 66.13% of users gave Vera Therapeutics an outperform vote. CompanyUnderperformOutperformVera TherapeuticsOutperform Votes4166.13% Underperform Votes2133.87% ORIC PharmaceuticalsOutperform Votes7275.00% Underperform Votes2425.00% Do analysts rate VERA or ORIC? Vera Therapeutics presently has a consensus price target of $64.67, indicating a potential upside of 176.71%. ORIC Pharmaceuticals has a consensus price target of $18.86, indicating a potential upside of 230.25%. Given ORIC Pharmaceuticals' higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Vera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.20ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of VERA or ORIC? 99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. 16.3% of Vera Therapeutics shares are owned by insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has stronger earnings & valuation, VERA or ORIC? Vera Therapeutics is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$95.99M-$2.75-8.50ORIC PharmaceuticalsN/AN/A-$100.70M-$1.82-3.14 Is VERA or ORIC more profitable? ORIC Pharmaceuticals' return on equity of -44.54% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -50.13% -39.50% ORIC Pharmaceuticals N/A -44.54%-40.72% Does the media refer more to VERA or ORIC? In the previous week, Vera Therapeutics had 8 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 16 mentions for Vera Therapeutics and 8 mentions for ORIC Pharmaceuticals. Vera Therapeutics' average media sentiment score of 1.42 beat ORIC Pharmaceuticals' score of 1.04 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ORIC Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, VERA or ORIC? Vera Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. SummaryVera Therapeutics and ORIC Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORIC vs. The Competition Export to ExcelMetricORIC PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$405.90M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-3.147.4422.4418.48Price / SalesN/A242.70393.95103.59Price / CashN/A65.8538.1834.62Price / Book1.676.516.774.25Net Income-$100.70M$143.21M$3.22B$248.23M7 Day Performance10.02%1.98%1.45%0.89%1 Month Performance3.25%6.89%3.96%3.53%1 Year Performance-38.80%-2.52%16.07%5.08% ORIC Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORICORIC Pharmaceuticals4.0006 of 5 stars$5.71+0.9%$18.86+230.2%-35.3%$405.90MN/A-3.1480Upcoming EarningsNews CoveragePositive NewsVERAVera Therapeutics2.9227 of 5 stars$21.11-0.8%$64.67+206.3%-40.9%$1.35BN/A-8.0940Upcoming EarningsNews CoveragePositive NewsGap DownTVTXTravere Therapeutics2.8971 of 5 stars$15.11+1.3%$32.08+112.3%+276.3%$1.34B$233.18M-3.69460News CoveragePositive NewsGPCRStructure Therapeutics2.2247 of 5 stars$23.10+6.2%$81.29+251.9%-31.5%$1.32BN/A-31.22136Upcoming EarningsNews CoveragePositive NewsHigh Trading VolumeMESOMesoblast1.9176 of 5 stars$10.28-4.1%$18.00+75.1%+72.7%$1.31B$5.67M0.0080Gap DownEVOEvotec1.8551 of 5 stars$3.58-0.6%$5.93+65.7%-19.1%$1.27B$777.05M0.004,200Upcoming EarningsShort Interest ↓Gap DownINDVIndivior3.3529 of 5 stars$8.81-2.2%$15.00+70.3%-34.5%$1.21B$1.19B-25.171,164Earnings ReportShort Interest ↑Analyst RevisionOCULOcular Therapeutix3.5926 of 5 stars$7.61+4.1%$16.38+115.2%+75.1%$1.21B$63.72M-5.77230Upcoming EarningsNews CoverageCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180AMPHAmphastar Pharmaceuticals4.5062 of 5 stars$23.50+0.6%$43.50+85.1%-40.8%$1.12B$731.97M7.831,620Upcoming EarningsPositive NewsARDXArdelyx4.5109 of 5 stars$4.56-5.4%$10.61+132.7%-13.9%$1.09B$333.62M-28.5090 Related Companies and Tools Related Companies Vera Therapeutics Competitors Travere Therapeutics Competitors Structure Therapeutics Competitors Mesoblast Competitors Evotec Competitors Indivior Competitors Ocular Therapeutix Competitors Calliditas Therapeutics AB (publ) Competitors Amphastar Pharmaceuticals Competitors Ardelyx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORIC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORIC Stock Free ORIC Stock Alerts